hims and hers semaglutide & to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny Hims offers cheapest GLP-1 weight-loss

Initially, three patients in the loading dose group and seven in the no loading dose group had GDS scores 5, decreasing to two patients in each group by study end

Facts: Stretching Your Dose Myth: Taking Wegovy every 10 days is a good way to taper off the medication

Medical Appropriateness: Will this work for someone my age

One study found no significant increase in NAION risk with semaglutide compared to other agents when using broad diagnostic criteria

Bourgeois S, Coenen S, Degroote L et al (2024) Harnessing beta cell regeneration biology for diabetes therapy

It remains an investigational drug currently being evaluated in Phase 3 clinical trials by Eli Lilly for the treatment of: Obesity (without diabetes) Type 2 diabetes Nonalcoholic fatty liver disease (NAFLD/NASH) Projected Approval Timeline Based on Phase 2 success and accelerated trials, Retatrutide could receive FDA approval as early as 2026 Eli Lilly is positioning it to directly compete with Tirzepatide (Mounjaro) and Semaglutide (Wegovy) Expected to be administered as a once-weekly injection Not Available for Research or Off-Label Use Retatrutide is not legally available on the gray market No legitimate research chemical suppliers offer it any listings claiming to sell Retatrutide are likely counterfeit or misbranded Because of its complex multi-receptor structure, DIY compounding is extremely risky and discouraged Athletic Use and WADA Considerations Like other GLP-1 agonists, Retatrutide is not currently banned by WADA However, its performance-enhancing effects (fat loss, appetite suppression, metabolic acceleration) could put it under scrutiny in the future Athletes in tested federations should proceed cautiously once the drug is commercialized Until Retatrutide clears regulatory approval, its use remains confined to clinical trial settings